TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04015518
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
Study: NCT04015518
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
Study: NCT04015518
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
Study: NCT04015518
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
Study: NCT04015518
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
Study: NCT03718390
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Study: NCT03718390
Drug: Formulation E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Capsule containing microcrystalline cellulose
Study: NCT03816553
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
Study: NCT03816553
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib will be administered 250mg orally, once daily until progression.
Study: NCT03525028
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
Study: NCT01090154
Drug: Cimzia
Normalized name: Cimzia
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
Study: NCT01079754
Drug: Spinal morphine 0.05 mg
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient received spinal morphine 0.05 mg
Study: NCT01079754
Drug: Spinal morphine 0.1 mg
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient received spinal morphine 0.1 mg
Study: NCT02759185
Drug: High THC cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three weeks of smoking cannabis containing more THC than CBD with amount smoked limited to no more than 1.8 g per day.
Study: NCT02759185
Drug: High CBD cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three weeks of smoking cannabis containing more CBD than THC with amount smoked limited to no more than 1.8 g per day.
Study: NCT02759185
Drug: Placebo cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three weeks of smoking cannabis with low levels of THC and CBD with smoking limited to no more than 1.8 per day.
Study: NCT02110745
Drug: Sevofluorane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different induction drugs and techniques
Study: NCT02110745
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different induction drugs and techniques
Study: NCT01226914
Drug: EVICEL
Normalized name: Evicel
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVICEL
Study: NCT03163576
Drug: Niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00477061
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00722384
Drug: bevasiranib
Normalized name: Bevasiranib
DrugBank: Bevasiranib (DB06642)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00722384
Drug: bevasiranib
Normalized name: Bevasiranib
DrugBank: Bevasiranib (DB06642)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
Study: NCT00004062
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02505451
Drug: dobutamine
Normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
Study: NCT01650545
Drug: Liposomal aerosol cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled form of immune suppression
Study: NCT01267084
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
Study: NCT01267084
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
Study: NCT01267084
Drug: Dexamethasone or equivalent steroid
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
Study: NCT00104065
Drug: CG53135-05, velafermin
DrugBank: Velafermin (DB06493)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02071602
Drug: CD-NP
Normalized name: CD-NP
DrugBank: Cenderitide (DB11777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized 1:1:1
Study: NCT03321461
Drug: TMTP1
Normalized name: Temoporfin
DrugBank: Temoporfin (DB11630)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Fluorescent sites will be removed
Study: NCT03321461
Drug: ICG
Normalized name: ICG136
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescent sites will be removed
Study: NCT00524524
Drug: ARQ 501
Normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IV Infusion; 450 mg/m2
Study: NCT01853787
Drug: Formoterol Fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
Study: NCT02175381
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
Study: NCT02175381
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
Study: NCT00432796
Drug: Dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
Study: NCT02013570
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
Study: NCT03919500
Drug: EPO
Normalized name: Epo B
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.
Study: NCT00623597
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5-3.0mg/kg po bid (starting dose) for 48 weeks
Study: NCT00623597
Drug: saquinavir [Invirase]
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/kg po bid (starting dose) for 48 weeks
Study: NCT03790618
Drug: 3,4-Methylenedioxymethamphetamine
Normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
Study: NCT03790618
Drug: methamphetamine
Normalized name: Methamphetamine
DrugBank: Metamfetamine (DB01577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Please see above.
Study: NCT03722940
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
Study: NCT01194934
Drug: NOX-A12
Normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg daily IV for 5 days
Study: NCT01194934
Drug: NOX-A12
Normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg daily IV for 5 days
Study: NCT01194934
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 µg/kg SC daily for 5 days
Study: NCT01194934
Drug: NOX-A12 in combination with Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Safe and efficacious dose regimen according to results of groups A and B
Study: NCT01573767
Drug: Fluticasone propionate 100mcg
Normalized name: FLUTICASONE PROPIONATE 100MCG INHL,ORAL,DISKUS,60
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
Study: NCT01573767
Drug: Vilanterol
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects will recieve 4 weeks via NDPI during treament period
Study: NCT01238562
Drug: YPEG-Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study: NCT01238562
Drug: YPEG-Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study: NCT01238562
Drug: YPEG-Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study: NCT01238562
Drug: YPEG-Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
Study: NCT01238562
Drug: YPEG-Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study: NCT03035734
Drug: BMS-986141 Form A Tablet
Normalized name: BMS dasatinib
DrugBank: BMS-986141 (DB14942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03035734
Drug: BMS-986141 Form B tablet (low dose)
Normalized name: ethinyl estradiol
DrugBank: BMS-986141 (DB14942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03035734
Drug: BMS-986141 Form B tablet (high dose)
Normalized name: BMS-986141
DrugBank: BMS-986141 (DB14942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT02668016
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg tablets taken orally once daily for one month.
Study: NCT03322098
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
Study: NCT03322098
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
Study: NCT01468441
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
Study: NCT01468441
Drug: Cetrorelix
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
Study: NCT02537834
Drug: Tofogliflozin
Normalized name: Tofogliflozin
DrugBank: Tofogliflozin (DB11824)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00119236
Drug: tanespimycin
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00119236
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02758613
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT02867163
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous or local administration of TXA, in any dosage
Study: NCT02537834
Drug: GLP-1 analogue
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04382144
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive a single injection of a local anesthetic into the common extensor origin.
Study: NCT01903681
Drug: Circadin 2 mg
Normalized name: ZINC OXIDE 173 mg in 1 mL TOPICAL CREAM [Circadia Circa-Shield Mineral Sunscreen SPF 30]
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First arm lower dose
Study: NCT01903681
Drug: Circadin 10 mg
Normalized name: ZINC OXIDE 173 mg in 1 mL TOPICAL CREAM [Circadia Circa-Shield Mineral Sunscreen SPF 30]
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Second arm higher dose
Study: NCT00775814
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
Study: NCT03207139
Drug: Ga-68 PSMA ligand
Normalized name: PSMA-11 Ga 68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq.
Study: NCT04443296
Drug: CCRT+TIL
Normalized name: CD8 enriched young TIL
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
Study: NCT04480567
Drug: BMN 307
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV Gene Therapy Infusion
Study: NCT02486679
Drug: Prostin (PGE2) tablets
Normalized name: Prostin VR
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00842075
Drug: pramlintide
Normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection (15 mcg initial dose)prior to meals
Study: NCT02329184
Drug: MYK-461
Normalized name: MYK-461
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01933880
Drug: Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
Study: NCT04051099
Drug: Dexmedetomidine plus propofol infusion
Normalized name: Propofol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion
Study: NCT02057913
Drug: Vinflunine
Normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
Study: NCT01853787
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
Study: NCT00762632
Drug: NILOTINIB
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
Study: NCT00762632
Drug: EVEROLIMUS
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus at 2,5 mg/day should be continued 25 weeks.
Study: NCT01393600
Drug: NBI-98854
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg powder in bottle once daily for 14 days
Study: NCT01393600
Drug: NBI-98854
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg powder in bottle once daily for 14 days
Study: NCT02789475
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine administration
Study: NCT02609646
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
Study: NCT02609646
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
Study: NCT02609646
Drug: Piperacillin-tazobactam combination product
Normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.